Free Trial

Stevanato Group (STVN) Competitors

Stevanato Group logo
€19.59
+0.58 (+3.05%)
(As of 11/1/2024 08:57 PM ET)

STVN vs. SOLV, SNN, PEN, BLCO, GKOS, INSP, TMDX, AXNX, PRCT, and NVST

Should you be buying Stevanato Group stock or one of its competitors? The main competitors of Stevanato Group include Solventum (SOLV), Smith & Nephew (SNN), Penumbra (PEN), Bausch + Lomb (BLCO), Glaukos (GKOS), Inspire Medical Systems (INSP), TransMedics Group (TMDX), Axonics (AXNX), PROCEPT BioRobotics (PRCT), and Envista (NVST). These companies are all part of the "medical equipment" industry.

Stevanato Group vs.

Stevanato Group (NYSE:STVN) and Solventum (NYSE:SOLV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends, earnings and community ranking.

Stevanato Group has a net margin of 11.27% compared to Solventum's net margin of 0.00%. Stevanato Group's return on equity of 10.89% beat Solventum's return on equity.

Company Net Margins Return on Equity Return on Assets
Stevanato Group11.27% 10.89% 6.33%
Solventum N/A N/A N/A

Stevanato Group has higher revenue and earnings than Solventum.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stevanato Group$1.17BN/A$157.62M$0.5039.18
SolventumN/AN/AN/AN/AN/A

Solventum has a consensus target price of $64.33, suggesting a potential downside of 11.22%. Given Solventum's higher possible upside, analysts plainly believe Solventum is more favorable than Stevanato Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stevanato Group
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Solventum
1 Sell rating(s)
8 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Stevanato Group received 26 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 62.79% of users gave Stevanato Group an outperform vote while only 6.67% of users gave Solventum an outperform vote.

CompanyUnderperformOutperform
Stevanato GroupOutperform Votes
27
62.79%
Underperform Votes
16
37.21%
SolventumOutperform Votes
1
6.67%
Underperform Votes
14
93.33%

In the previous week, Solventum had 10 more articles in the media than Stevanato Group. MarketBeat recorded 11 mentions for Solventum and 1 mentions for Stevanato Group. Solventum's average media sentiment score of 0.86 beat Stevanato Group's score of 0.00 indicating that Solventum is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Stevanato Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Solventum
6 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Stevanato Group beats Solventum on 8 of the 11 factors compared between the two stocks.

Get Stevanato Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for STVN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STVN vs. The Competition

MetricStevanato GroupSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market CapN/A$4.45B$5.40B$19.26B
Dividend YieldN/A42.37%5.15%3.54%
P/E Ratio39.1837.84113.7641.40
Price / SalesN/A64.751,483.0414.66
Price / Cash22.2649.2739.7120.84
Price / Book4.724.214.665.39
Net Income$157.62M$11.52M$119.06M$985.39M
7 Day Performance13.43%1.05%0.79%-0.70%
1 Month Performance-2.05%0.94%5.65%-0.97%
1 Year Performance-24.77%39.40%36.80%25.06%

Stevanato Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STVN
Stevanato Group
1.0467 of 5 stars
€19.59
+3.1%
N/A-23.9%$0.00$1.17B39.185,635Upcoming Earnings
SOLV
Solventum
1.612 of 5 stars
$73.19
0.0%
$64.33
-12.1%
N/A$12.64B$8.25B0.0022,000Upcoming Earnings
SNN
Smith & Nephew
1.9055 of 5 stars
$28.37
-3.8%
N/A+13.1%$12.40B$5.64B13.7718,452Analyst Downgrade
News Coverage
Gap Down
PEN
Penumbra
3.9 of 5 stars
$204.71
-0.9%
$220.17
+7.6%
+20.2%$7.94B$1.13B602.094,200Earnings Report
Analyst Forecast
Analyst Revision
News Coverage
BLCO
Bausch + Lomb
2.3267 of 5 stars
$20.46
+1.4%
$20.27
-0.9%
+24.2%$7.20B$4.50B-15.7413,300Analyst Forecast
Short Interest ↑
Analyst Revision
News Coverage
GKOS
Glaukos
3.6575 of 5 stars
$130.59
+0.1%
$130.45
-0.1%
+89.5%$6.58B$341.73M-40.06780Upcoming Earnings
Insider Selling
INSP
Inspire Medical Systems
4.7122 of 5 stars
$195.20
-0.1%
$219.58
+12.5%
+22.0%$5.82B$624.80M1,084.441,011Upcoming Earnings
News Coverage
TMDX
TransMedics Group
4.2511 of 5 stars
$125.17
+2.6%
$174.30
+39.3%
+116.6%$4.18B$241.62M3,129.25210Earnings Report
Analyst Forecast
Analyst Revision
News Coverage
AXNX
Axonics
3.7971 of 5 stars
$70.23
-0.1%
$69.57
-0.9%
+35.9%$3.58B$408.81M-1,755.31610Upcoming Earnings
Short Interest ↓
Positive News
PRCT
PROCEPT BioRobotics
1.3718 of 5 stars
$68.77
+2.9%
$86.40
+25.6%
+235.0%$3.54B$176.58M-33.38626Earnings Report
Analyst Forecast
Insider Selling
Analyst Revision
News Coverage
High Trading Volume
NVST
Envista
4.3067 of 5 stars
$18.89
-0.7%
$19.88
+5.2%
-8.9%$3.25B$2.53B-2.4512,800Earnings Report
Analyst Forecast
Analyst Revision
News Coverage

Related Companies and Tools


This page (NYSE:STVN) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners